Oncology
 |
|
26 february 2015 11:03:40 |
| Targeted therapies: DNA polymerase ?--a new target for synthetic lethality? (Nature Clinical Practice Oncology) |
|
Tweet Many cancers harbour deficiencies in DNA double-strand break (DSB) repair; in particular, aberrations affecting components of the homologous recombination (HR) pathway, such as BRCA1 and BRCA2, and ATM, are common. However, alternate DSB-repair pathways, such as non-homologous end-joining (NHEJ), enable these cancers to persist. Agents |
| 82 viewsCategory: Oncology |
 Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing (BMC Cancer)The transcriptional modulator BCL6 as a molecular target for breast cancer therapy (Oncogene) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
